文献速递前列腺癌

PRI-MUS评分系统的外部验证:OPTIMUM随机对照试验的二次分析

External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial.
PubMed 文献 · J Urol · 2026-04-28

结果显示,按针道和病灶分析,PRI-MUS 1-2分 vs 3-5分的AUC均为0.78,敏感性和阴性预测值较高,支持其作为微超声引导穿刺的风险分层工具。

要点

  • PRI-MUS评分在针道水平诊断csPCa的AUC为0.78(95%CI 0.76-0.8),敏感性72%、特异性74%、阴性预测值93%。
  • 病灶水平AUC为0.78(95%CI 0.73-0.82),敏感性92%、特异性34%、阴性预测值83%。

核心结论

  • PRI-MUS评分系统在针道和病灶水平均对csPCa表现出高敏感性和高阴性预测值,支持其作为微超声引导穿刺风险分层工具的有效性。

主要发现

  • 针道水平分析4590个穿刺针道,PRI-MUS 1-2分 vs 3-5分的敏感性72%、特异性74%、阳性预测值37%、阴性预测值93%,AUC 0.78(95%CI 0.76-0.8)。
  • 病灶水平分析322个病灶,PRI-MUS 1-2分 vs 3-5分的敏感性92%、特异性34%、阳性预测值55%、阴性预测值83%,AUC 0.78(95%CI 0.73-0.82)。

关键数值与推荐

  • PRI-MUS 1-2分 vs 3-5分用于预测csPCa:针道水平敏感性72%、特异性74%、阳性预测值37%、阴性预测值93%;病灶水平敏感性92%、特异性34%、阳性预测值55%、阴性预测值83%。

临床怎么用

  • PRI-MUS评分可作为微超声引导前列腺穿刺的风险分层工具,高阴性预测值有助于识别低风险患者。

局限性

  • 本研究为OPTIMUM试验的二次分析,外部验证结论需进一步在前瞻性多中心队列中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Micro-ultrasonography (microUS)-guided biopsy has emerged as an alternative to MRI fusion-guided biopsy for the diagnosis of prostate cancer. This study aimed to externally validate the PRI-MUS (Prostate Risk Identification using Micro-Ultrasound) scoring system for predicting clinically significant prostate cancer (csPCa) using data from the OPTIMUM trial. MATERIALS AND METHODS: A secondary analysis of the OPTIMUM trial was conducted to evaluate the diagnostic performance of the PRI-MUS scoring system. The analysis included patients who underwent microUS-guided prostate biopsy, with each core assigned a PRI-MUS score. The diagnostic performance of the PRI-MUS scoring system for identifying csPCa was assessed at per-core and per-lesion levels. RESULTS: Three hundred forty-seven patients receiving microUS-guided biopsy were included. At the per-core level, 4590 biopsy cores were analyzed and assigned a PRI-MUS score. When comparing PRI-MUS 1 to 2 vs 3 to 5, the sensitivity, specificity, positive predictive value, and negative predictive value (NPV) for detecting csPCa were 72%, 74%, 37%, and 93%, respectively. The AUC was 0.78 (95% CI: 0.76 to 0.8). At the per-lesion level, 322 lesions were analyzed. When comparing PRI-MUS 1 to 2 vs 3 to 5, the corresponding sensitivity, specificity, positive predictive value, and NPV were 92%, 34%, 55%, and 83%, respectively. The AUC was 0.78 (95% CI: 0.73-0.82). Nineteen high-risk anterior lesions were biopsied, with csPCa detected in 11 (57.8%). CONCLUSIONS: The PRI-MUS scoring system demonstrated high sensitivity and NPV for diagnosing csPCa at both the per-core and per-lesion levels, supporting its validity as a risk-stratification tool for microUS-guided biopsy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lazarovich A, Guer M, Luger F, et al. External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial. J Urol. 2026. PMID: 42048785. doi:10.1097/JU.0000000000005082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。